Dexcel Pharma Technologies Company Profile
Dexcel is a research-based international specialty pharmaceutical company dedicated to treating and preventing human disease through discovery, development, manufacturing and commercialization of innovative pharmaceutical products based on sophisticated proprietary controlled release oral solid dosage form drug delivery technologies. Dexcel was founded in Israel in 1965 and is a private healthcare company, fully owned and operated by its President and CEO, Mr. Dan Oren (See "Executive Team")
Location
Wainwright Building 229 West Bute Street Suite 407
Norfolk
Virginia
23510
United States of America
Contact
Phone: 1-757- 627- 0066
News Articles
PerioChip® Antibiotic-Free Adjunctive Treatment for Periodontal Disease Available Online in the U.S.
Dexcel Pharma Technologies, Ltd. has announced the online availability of PerioChip® for dental professionals in the U.S. market through its new website at www.PerioChip.com/orde...
Cynapsus Therapeutics Appoints Two New Directors
TORONTO, ONTARIO -- (Marketwired) -- 05/09/13 -- Cynapsus Therapeutics Inc. (TSX VENTURE: CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used...
Pharma 3.0 Pulls Companies into the Digital Future
Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0. Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drug...
Big pharma companies BMS and Merck are pharma partnering on Daclatasvir
Big pharma company, Bristol-Myers Squibb, is pharma partnering with another big pharma company, Merck, to develop Daclatasvir to treat Hepatitis C. The big pharma companies will work on the hepatitis...
Merck enter pharma partnering pact with Ra Pharma for cyclomimetics
Ra Pharmaceuticals has entered into a pharma partnering deal with Merck, a top 50 big pharma corporation, focused on the development of Cyclomimetics, a new class of compounds that have the diversity...
Verona Pharma plc: Analyst Presentation on the Company Website
LONDON, April 10, 2013 /PRNewswire/ -- Verona Pharma plc ("Verona Pharma" or the "Company") Verona Pharma plc (VRP: London Stock Exchange) ("Verona Pharma", or the "Company"), the biotechnology co...
Big Pharma performance continues to receive muted reviews from various analysts and industry commentators. Pharma Reform starts with an analysis of drug approvals in 2012 by FDA. It is TRUE that 35 dr...
Bad Pharma by Dr Ben Goldacre; the mechanics of a mediocre argument
Nick Broughton discusses Dr Ben Goldacre’s latest book, Bad Pharma, and comments on why he believes it was a wasted opportunity for the pharma industry. If you are working in pharma and are not awa...
Drugs and Medications
Omeprazole [Dexcel Pharma Technologies Ltd.]
Omeprazole Delayed Release Tablets, 20 mg
Omeprazole [Dexcel Pharma Technologies Ltd.]
Omeprazole Delayed Release Tablets, 20 mg
Fluoride [Libertas Pharma, Inc.]
Fluoride Chewable Tablets 0.5 mg
Fluoride [Libertas Pharma, Inc.]
Fluoride Chewable Tablets 1 mg
Metoprolol tartrate [Med-Health Pharma, LLC]
Metoprolol Tartrate Tablets, USP
PubMed Articles
Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...
Is pharma running out of brainy ideas?
Clinical Trials
To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.
Pharma-Pen (Formerly Innoject) Auto-Injectory TIV
The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...
To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions
To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.
This is 2-armed parallel group, prospective, randomized, open-label, multicenter Phase 3 controlled trial to establish the efficacy and safety of conversion from maintenance immunosuppress...
Development of a New Method for Analgesia
Aim: To examine a new method to perform local anesthesia in order to diminish the inconvenience by the procedure in patients before performing intubation or oesophagogastroduodenoscopy.
Companies
Dexcel Pharma Technologies, Ltd.
Founded in 1968 and headquartered in Or Akiva, Israel, Dexcel Pharma is a privately-held, international specialty pharmaceutical company. It has a presence in 20 countrie...
Dexcel is a research-based international specialty pharmaceutical company dedicated to treating and preventing human disease through discovery, development, manufacturing and commercialization of inno...
H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and...
LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...
Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies,...
More Information about "Dexcel Pharma Technologies" on BioPortfolio
We have published hundreds of Dexcel Pharma Technologies news stories on BioPortfolio along with dozens of Dexcel Pharma Technologies Clinical Trials and PubMed Articles about Dexcel Pharma Technologies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dexcel Pharma Technologies Companies in our database. You can also find out about relevant Dexcel Pharma Technologies Drugs and Medications on this site too.